CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
Rhea-AI Summary
CervoMed (NASDAQ: CRVO), a clinical-stage biotech focused on age-related brain disorders, will join the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit.
Management will host a virtual fireside chat and one-on-one investor meetings on Monday, June 15, 2026, with a webcast available via the company’s investor section.
Positive
- None.
Negative
- None.
News Market Reaction – CRVO
In the Jun 12 session, CRVO gained 0.41%, reflecting a mild positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 10 | Financing & strategy | Positive | -22.1% | Private placement to raise $10.5M and fund neflamapimod toward Phase 3. |
| May 18 | Quarterly earnings update | Negative | -11.6% | Q1 2026 results with $12.9M cash and $8.0M net loss disclosed. |
| Apr 22 | Clinical MRI data | Positive | +0.8% | Phase 2b MRI data showing basal forebrain volume and connectivity benefits. |
| Apr 07 | Program update & biomarkers | Positive | -3.5% | Neflamapimod program update and biomarker data at LBDA annual meeting. |
| Mar 19 | Subgroup efficacy data | Positive | -0.2% | AD/PD 2026 data highlighting greater benefit in low pTau181 DLB subgroup. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and financing news often saw weak or negative next-day price reactions.
Over the past few months, CervoMed has focused on advancing neflamapimod toward Phase 3 in dementia with Lewy bodies. A private placement announced on Jun 10, 2026 aimed to raise about $10.5M and extend cash runway into Q2 2027, yet the stock fell 22.15%. Q1 2026 results on May 18 highlighted $12.9M cash and an $8.0M net loss, followed by an 11.63% decline. Multiple data updates from the RewinD‑LB Phase 2b program in March–April produced mostly modest or negative reactions despite clinically positive signals.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, being held virtually on Monday, June 15, 2026.
Presentation Details
Format: Fireside Chat
Date: Monday, June 15, 2026
Time: 7:00 – 7:30 AM ET
Webcast Link: https://journey.ct.events/view/9162603c-eb01-4cb3-85b7-36814fad7928
The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.
About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology, and the Company announced alignment with the FDA on a potential registration path for neflamapimod in DLB in November 2025. Initiation of a Phase 3 trial in DLB is subject to the establishment of a partnership and/or additional financing. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.
Contacts
Media:
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431
Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902
